GW Pharmaceuticals to Report Fourth Quarter and Year-End Financial Results and Host Conference Call on 27 November, 2018
November 06 2018 - 7:00AM
GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a
biopharmaceutical company focused on discovering, developing and
commercializing novel therapeutics from its proprietary cannabinoid
product platform, will announce on 27 November, 2018 its fourth
quarter and year-end financial results for the period ending 30
September, 2018. GW will also host a conference call the same day
at 4:30 p.m. EST. Conference call information will be provided in
the financial results press release. A replay of the call will also
be available through the Company's website (www.gwpharm.com)
shortly after the call.
About GW Pharmaceuticals plc and
Greenwich Biosciences, Inc.Founded in 1998, GW is a
biopharmaceutical company focused on discovering, developing and
commercializing novel therapeutics from its proprietary cannabinoid
product platform in a broad range of disease areas. GW, along with
its U.S. subsidiary Greenwich Biosciences, has received U.S. FDA
approval for EPIDIOLEX (cannabidiol) oral solution for the
treatment of seizures associated with Lennox-Gastaut syndrome (LGS)
or Dravet syndrome in patients two years of age or older. The
Company has submitted a regulatory application in Europe for the
adjunctive treatment of seizures associated with LGS and Dravet
syndrome. The company continues to evaluate EPIDIOLEX in additional
rare epilepsy conditions and currently has an ongoing clinical
trial in tuberous sclerosis complex (TSC). GW commercialized the
world’s first plant-derived cannabinoid prescription drug, Sativex®
(nabiximols), which is approved for the treatment of spasticity due
to multiple sclerosis in numerous countries outside the United
States and for which the company is now planning a U.S. Phase 3
trial. The Company has a deep pipeline of additional cannabinoid
product candidates which includes compounds in Phase 1 and 2 trials
for epilepsy, glioblastoma, and schizophrenia. For further
information, please visit www.gwpharm.com.
Enquiries:
GW
Pharmaceuticals plc |
|
Stephen Schultz, VP Investor Relations (U.S.) |
917
280 2424 / 401 500 6570 |
|
|
|
|
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Apr 2023 to Apr 2024